Mayne Pharma Group's revenue is forecast to decline at 2.1% per annum while its annual earnings are expected to grow at 44.6% per year. EPS is expected to grow by 50.1% per annum.
Key information
44.6%
Earnings growth rate
50.11%
EPS growth rate
Pharmaceuticals earnings growth
19.0%
Revenue growth rate
-2.1%
Future return on equity
n/a
Analyst coverage
Low
Last updated
04 Aug 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
OTCPK:MAYN.F - Analysts future estimates and past financials data (AUD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2028
389
-35
35
43
2
6/30/2027
380
83
16
24
2
6/30/2026
400
-60
2
8
2
12/31/2025
407
-82
-1
22
N/A
9/30/2025
408
-86
-6
20
N/A
6/30/2025
408
-90
-12
17
N/A
3/31/2025
411
-104
-12
9
N/A
12/31/2024
414
-118
-12
0
N/A
9/30/2024
401
-143
-24
-7
N/A
6/30/2024
388
-169
-36
-15
N/A
12/31/2023
319
-274
-34
-15
N/A
9/30/2023
251
-296
-148
-29
N/A
6/30/2023
184
-317
-262
-43
N/A
12/31/2022
59
-257
-287
-64
N/A
9/30/2022
108
-233
-153
-36
N/A
6/30/2022
157
-209
-19
-7
N/A
3/31/2022
250
-151
-13
3
N/A
12/31/2021
342
-93
-7
13
N/A
9/30/2021
372
-151
14
36
N/A
6/30/2021
401
-208
34
59
N/A
3/31/2021
420
-232
56
82
N/A
12/31/2020
439
-256
78
106
N/A
9/30/2020
448
-174
72
109
N/A
6/30/2020
457
-93
65
113
N/A
3/31/2020
467
-196
61
109
N/A
12/31/2019
478
-300
56
106
N/A
9/30/2019
502
-290
N/A
106
N/A
6/30/2019
525
-279
N/A
107
N/A
3/31/2019
543
-118
N/A
117
N/A
12/31/2018
561
43
N/A
127
N/A
9/30/2018
546
-46
N/A
124
N/A
6/30/2018
530
-134
N/A
121
N/A
3/31/2018
526
-146
N/A
111
N/A
12/31/2017
521
-158
N/A
100
N/A
9/30/2017
547
-35
N/A
42
N/A
6/30/2017
573
89
N/A
-15
N/A
3/31/2017
504
90
N/A
-30
N/A
12/31/2016
435
91
N/A
-44
N/A
9/30/2016
351
64
N/A
5
N/A
6/30/2016
267
37
N/A
54
N/A
3/31/2016
238
30
N/A
49
N/A
12/31/2015
209
23
N/A
44
N/A
9/30/2015
175
15
N/A
33
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MAYN.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).
Earnings vs Market: MAYN.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MAYN.F is expected to become profitable in the next 3 years.
Revenue vs Market: MAYN.F's revenue is expected to decline over the next 3 years (-2.1% per year).
High Growth Revenue: MAYN.F's revenue is forecast to decline over the next 3 years (-2.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MAYN.F's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/21 12:04
End of Day Share Price
2026/08/13 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayne Pharma Group Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.